HERA

Nov 16 2024HEALTH

Managing Acalabrutinib Side Effects: Real-World Advice from French Experts

Acalabrutinib, a newer medication for chronic lymphocytic leukemia, is safer than older options. However, managing its side effects can be tricky. A group of French healthcare professionals—including hematologists, pharmacists, and doctors specializing in heart and skin issues—decided to find practi

reading time less than a minute
Nov 16 2024HEALTH

The Benefits of Taking Meds on Time for Heart Patients

You know how sometimes people don’t take their medicines as they should? Well, this can be a big problem for folks with heart diseases, especially in places like Mexico, Thailand, and China. A recent study looked into what could happen if these patients took their meds properly. The results? Big sav

reading time less than a minute
Nov 16 2024HEALTH

Comparing Two CAR-T Therapies: Liso-cel and Axi-cel in LBCL

At a single hospital, patients with large B-cell lymphoma (LBCL) who didn't respond to initial treatments were given either lisocabtagene maraleucel (liso-cel) or axicabtagene ciloleucel (axi-cel). Liso-cel is newer and not widely studied outside clinical trials yet. From June 2021 to September 2022

reading time less than a minute
Nov 16 2024HEALTH

Concussion and Eye Focus: A Timing Study

Ever wondered how quickly to treat concussion-related eye focus issues? The CONCUSS study is set to find out. This project is a randomized clinical trial comparing two ways to fix convergence insufficiency, a common problem after concussions. One group gets immediate treatment, while the other waits

reading time less than a minute
Nov 15 2024HEALTH

Porphyrin Nanostructures: A New Hope for Cancer Treatment

Imagine having a tiny, smart tool that can target cancer cells with precision and efficiency. That's what porphyrin-based nanoscale metal-organic frameworks (MOFs) are doing in the world of cancer treatment. These tiny structures are like superheroes, combining the powers of photodynamic therapy and

reading time less than a minute
Nov 15 2024HEALTH

Prostate Cancer Treatments: A Cost-Effective Approach for Developing Countries

In Brazil, prostate cancer affects a large number of men each year, with around 71, 730 cases reported annually. The main treatment for advanced hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, advanced drugs called androgen receptor pathway inhibitors (ARPIs) are no

reading time less than a minute
Nov 14 2024CELEBRITIES

Actor Dave Coulier from 'Full House' Fights Blood Cancer

Dave Coulier, who starred as Joey Gladstone in the beloved sitcom "Full House, " recently opened up about his battle with stage 3 non-Hodgkin lymphoma. This type of blood cancer starts in the lymphatic system. The actor first noticed something was not right about a month ago when he developed sympto

reading time less than a minute
Nov 14 2024HEALTH

Brain's Immune Battle: The Complex Case of Quadruple Antibody Encephalitis

Imagine your brain is a city, and suddenly, its own defense system turns against it. That's what happens in autoimmune encephalitis (AE). Usually, your immune system protects you, but in AE, it mistakenly attacks parts of your brain, causing weird symptoms like personality changes, memory loss, seiz

reading time less than a minute
Nov 14 2024HEALTH

Turning the Tide: New Hope for Sickle Cell Treatment

Sickle cell disease, known for its intense pain, might soon see a breakthrough. The solution lies in boosting fetal hemoglobin in red blood cells. While hydroxyurea can do this, especially for kids, scientists are now focusing on something revolutionary: gene therapy. This advanced technique could c

reading time less than a minute
Nov 13 2024HEALTH

Could CT Scans Predict Recurrence After Anal Cancer Treatment?

It's a dicey situation for many people with anal squamous cell carcinoma (ASCC). Even after treatment with chemoradiotherapy (CRT), about 3 in 10 patients face a recurrence. Unfortunately, the current tools doctors use to predict who might relapse aren't very effective. So, a group of researchers de

reading time less than a minute